JPRN-UMIN000027701
Recruiting
N/A
Multicenter study on clinicopathological features, molecular genetic abnormalities, treatment and prognosis of gastrointestinal malignant lymphomas - Multicenter study on clinicopathological features, molecular genetic abnormalities, treatment and prognosis of gastrointestinal malignant lymphomas
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University0 sites700 target enrollmentJune 9, 2017
ConditionsGastrointestinal malignant lymphoma
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Gastrointestinal malignant lymphoma
- Sponsor
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
- Enrollment
- 700
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who reject this research.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Multicenter study of clinical characteristics and prognosis in subjects with acute myocardial infarctioacute myocardial infarctionJPRN-UMIN000025493Department of Cardiology, Kasugai Municipal Hospital1,300
Completed
N/A
Multicenter cohort study of clinical feature, treatment modalities and prognosis of non-B non-C hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007570The University of Tokyo5,000
Recruiting
N/A
Multi-center observational study to investigate the effect of immune checkpoint inhibitors on MSI-H/dMMR solid tumorsMSI-H/dMMR solid tumorJPRN-UMIN000044728ational Cancer Center200
Recruiting
N/A
Multicenter study for elucidating the pathophysiology of respiratory diseases using integrative omics analysis including the TGFb signal transduction system and genetic information analysisJPRN-UMIN000043539Department of Respirology, Graduate School of Medicine, Chiba University60
Recruiting
Phase 4
A study to understand T2D patient characteristics with respect to medicines and clinical featuresCTRI/2022/10/046335ovo Nordisk Pharma Gulf FZE